HC Wainwright Research Analysts Lower Earnings Estimates for Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities research analysts at HC Wainwright cut their Q4 2024 EPS estimates for shares of Eton Pharmaceuticals in a report released on Friday, October 4th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.01) per share for the quarter, down from their previous estimate of $0.01. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q1 2025 earnings at $0.12 EPS, Q2 2025 earnings at $0.13 EPS, Q3 2025 earnings at $0.16 EPS and Q4 2025 earnings at $0.18 EPS.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.05). Eton Pharmaceuticals had a negative net margin of 21.31% and a negative return on equity of 43.62%. The firm had revenue of $9.07 million during the quarter, compared to analysts’ expectations of $10.00 million.

Separately, Craig Hallum upped their target price on Eton Pharmaceuticals from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, October 4th.

Eton Pharmaceuticals Stock Up 1.4 %

Shares of ETON opened at $7.40 on Monday. Eton Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $7.66. The company has a market capitalization of $190.11 million, a PE ratio of 185.00 and a beta of 1.31. The company has a 50-day simple moving average of $4.86 and a 200-day simple moving average of $3.98.

Insider Activity

In other news, major shareholder Opaleye Management Inc. acquired 11,248 shares of Eton Pharmaceuticals stock in a transaction dated Monday, October 7th. The shares were acquired at an average cost of $7.22 per share, with a total value of $81,210.56. Following the purchase, the insider now directly owns 2,730,000 shares of the company’s stock, valued at approximately $19,710,600. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders purchased 85,600 shares of company stock valued at $462,674 in the last ninety days. Company insiders own 14.89% of the company’s stock.

Institutional Trading of Eton Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Thompson Siegel & Walmsley LLC acquired a new position in Eton Pharmaceuticals during the 2nd quarter worth $420,000. Acadian Asset Management LLC boosted its holdings in shares of Eton Pharmaceuticals by 13.7% in the 1st quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock valued at $585,000 after buying an additional 18,898 shares during the period. Aristides Capital LLC bought a new position in Eton Pharmaceuticals in the second quarter worth about $658,000. Opaleye Management Inc. raised its position in shares of Eton Pharmaceuticals by 4.1% during the 4th quarter. Opaleye Management Inc. now owns 2,529,887 shares of the company’s stock worth $11,081,000 after purchasing an additional 99,617 shares during the period. Finally, Nantahala Capital Management LLC acquired a new position in shares of Eton Pharmaceuticals during the second quarter valued at $3,095,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.